Marketing-authorisation holder · United States
Hikma
158 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
158 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 158
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ABIRATERONE ACETATE125mg | 250mg | 500mg · Tablet | Abiraterone | United States | Marketed | 2018 |
| ADENOSINE3mg/ml · Injectable | Adenosine | United States | Marketed | 2004 |
| ALENDRONATE SODIUM70mg base/75ml · Solution | Alendronic acid | United States | Marketed | 2013 |
| ALPRAZOLAM1mg/ml · Concentrate | Alprazolam | United States | Marketed | 1993 |
| ALPROSTADIL0.5mg/ml · Injectable | Alprostadil | United States | Marketed | 1998 |
| AMICAR1gm | 500mg · Tablet | Aminocaproic acid | United States | Marketed | 1964 |
| AMICAR0.25gm/ml · Solution | Aminocaproic acid | United States | Marketed | 1964 |
| AMINOCAPROIC500mg · Tablet | Aminocaproic acid | United States | Not marketed | 2001 |
| AMOXICILLIN125mg/5ml | 200mg/5ml | 250mg/5ml | 400mg/5ml · For suspension | Amoxicillin | United States | Marketed | 1978 |
| AMOXICILLIN AND CLAVULANATE POTASSIUM125mg/5ml; 31.25mg base/5ml | 200mg/5ml; 28.5mg base/5ml | 250mg/5ml; 62.5mg base/5ml | 400mg/5ml; 57mg base/5ml | 600mg/5ml; 42.9mg base/5ml · For suspension | Amoxicillin, Clavulanic acid | United States | Marketed | 2002 |
| ATIVAN2mg/ml | 4mg/ml · Injectable | Lorazepam | United States | Marketed | 1980 |
| AZATHIOPRINE SODIUM100mg base/vial · Injectable | Azathioprine | United States | Marketed | 1995 |
| AZTREONAM1gm/vial | 2gm/vial | 500mg/vial · Injectable | Aztreonam | United States | Marketed | 2010 |
| BALSALAZIDE DISODIUM750mg · Capsule | Balsalazide | United States | Marketed | 2007 |
| BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE3mg/ml; 3mg base/ml · Injectable | Betamethasone | United States | Marketed | 2009 |
| BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE0.25% | 0.5% | 0.75% · Injectable | Bupivacaine | United States | Marketed | 2002 |
| BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE0.7mg base; 0.18mg base | 1.4mg base; 0.36mg base | 11.4mg base; 2.9mg base | 2.9mg base; 0.71mg base | 2mg base; 0.5mg base | 5.7mg base; 1.4mg base | 8.6mg base; 2.1mg base | 8mg base; 2mg base · Tablet | Buprenorphine, Naloxone | United States | Marketed | 2013 |
| BUTORPHANOL TARTRATE1mg/ml | 2mg/ml · Injectable | Butorphanol | United States | Marketed | 1998 |
| CAFCIT30mg base/3ml (eq 10mg base/ml) · Solution | Caffeine | United States | Marketed | 1999 |
| CAFCIT30MG BASE/3ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Caffeine | United States | Not marketed | 1999 |
| CARBOPLATIN150mg/vial | 450mg/vial | 50mg/vial · Injectable | Carboplatin | United States | Not marketed | 2004 |
| CEFAZOLIN SODIUM2gm base/vial | 3gm base/vial · Powder | Cefazolin | United States | Marketed | 2022 |
| CEFAZOLIN SODIUM100GM BASE/VIAL | 10GM BASE/VIAL | 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 1GM BASE/VIAL | 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 20GM BASE/VIAL | 20GM BASE/VIAL **Federal Register determination that product wa · Injectable | Cefazolin | United States | Marketed | 1988 |
| CEFOTETAN10gm base/vial | 1gm base/vial | 2gm base/vial · Injectable | Cefotetan | United States | Marketed | 2007 |
| CEFOXITIN10GM BASE/VIAL | 1GM BASE/VIAL | 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 2GM BASE/VIAL | 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Injectable | Cefoxitin | United States | Marketed | 2000 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 158 | 154 | 4 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.